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Abstract
Prostate cancer treatment presents multiple challenges that can negatively affect health-related 
quality of life (HrQoL), and which may be further compromised by maladaptive personality styles 
and psychological adjustment difficulties. This study examined the utility of a comprehensive 
psychosocial screening tool to identify psychosocial traits that prospectively predict HrQoL status 
among men treated for localized prostate cancer. The Millon Behavioral Medicine Diagnostic 
(MBMD) was administered to 66 men (mean age 68 years, 59% Caucasian) treated by either 
radical prostatectomy or radiotherapy along with standard measures of general and prostate 
cancer-specific quality of life assessed at a 12-month follow-up. Higher scores on both summary 
MBMD Management Guides (Adjustment Difficulties and Psych Referral) and higher scores on 
personality styles characterized by avoidance, dependency, depression, passive aggressiveness and 
self-denigration predicted lower HrQoL (β range = −.21 to −.50). Additionally, higher scores on 
the MBMD Depression, Tension-Anxiety and Future Pessimism scales predicted lower HrQoL. 
Finally, higher scores on the MBMD Intervention Fragility and Utilization Excess scale, also 
consistently predicted poorer mental and physical health functioning over time. These results point 
to the utility of the MBMD to help screen for potential impairments in mental and physical health 
functioning in men undergoing treatment for prostate cancer.
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Introduction
Psychosocial factors can impact mental and physical health outcomes among numerous 
cancer patient populations, including men diagnosed with and treated for prostate cancer 
(Krupski & Litwin, 2007). Prostate cancer treatments cause acute and chronic side effects 
including urinary, bowel and erectile dysfunction, fatigue and impaired physical functioning 
(Potosky et al., 2007; Stanford et al., 2000). Compromises in health-related quality of life 
(HrQoL) and impairments in mental health functioning are also a persistent source of 
concern and bother (Penson et al., 2003; Schover et al., 2002; Cooperberg et al., 2003; Wei 
et al., 2002). Treatment for PC often results in a number of disease- and treatment-related 
side effects that challenge HrQOL across multiple domains, including physical health, 
psychological and emotional well-being, sexual and social functioning (Althof et al., 2003; 
Dahn et al., 2004; Perez et al., 2002; Schover et al., 2002, Weber & Sherwill-Navarro, 
2005). While not all men treated for prostate cancer report extended periods of compromised 
HrQoL this may be the case in a substantial subgroup of cases and may persist for years 
after treatment.
Individual difference factors related to psychological adjustment have been shown to predict 
HrQoL over time in persons with cancer, and in men with PC in particular (e.g., levels of 
depression and anxiety; Howlett et al., 2010; Nelson, Choi, Mulhall, & Roth, 2007). 
However, less is known about the predictive role of longer-standing personality styles in 
HrQoL in men treated with PC (Siegel et al., 2007). Given that optimal adjustment after 
treatment may require the ability to communicate sexual and other health concerns with 
partners and health care professionals (Badr & Taylor, 2009; Kershaw et al., 2008; Manne et 
al., 2010; Northouse et al., 2007) it is plausible that personality styles characterized by 
dejection, avoidance, passivity, dependency, poor communication skills (passive-
aggressiveness) or low self-regard, may be associated with the poorest HrQoL outcomes. 
However, no prior work has examined such associations in the context of men treated for 
PC. Assessing psychosocial factors may help identify men at risk for poorer mental and 
physical health outcomes after PC treatment and promote more adaptive health outcomes 
and optimize patient management.
Although measures have been developed to tap many of the psychosocial variables that 
could individually predict the course of HrQoL in men with PC, a comprehensive set of 
independent assessments of psychosocial functioning that involves multiple mood, stress, 
personality and interpersonal measures may overburden patients. The Millon Behavioral 
Medicine Diagnostic (MBMD) is a broadband measure developed specifically for medical 
patients and provides two global summary scales and a thorough assessment of psychosocial 
factors (e.g., personality/coping styles and treatment-related behaviors) that may influence 
adjustment (Millon et al., 2001). The MBMD was shown to predict adjustment and health 
behaviors in numerous medical patient populations including patients with HIV/AIDS 
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(Cruess et al., 2007; Burbridge et al., 2011) and cardiovascular disease (Cruess et al., 2010; 
Farrell et al., 2011). However, no studies have tested the predictive validity of the MBMD in 
the context of men with PC.
This study tests the utility of the MBMD to predict HrQoL across a one-year study period 
among men treated for localized PC participating in a larger study examining adjustment to 
treatment in this population. The MBMD was added to the test battery on a post-hoc basis 
midway through the study. However, because this larger study collected data from several 
commonly used and well-validated HrQoL measures along with comprehensive 
sociodemographic and medical information, we had a unique opportunity to examine the 
predictive utility of the MBMD in this population. In our main analyses, we examined the 
two global summary MBMD Management Guides (Adjustment Difficulties, Psych 
Referral), designed to identify patients at greater risk of adjustment to illness and those 
needing adjuvant psychosocial services, as predictors of commonly employed HrQoL 
measures for PC patients. We hypothesized that higher scores on the two MBMD 
Management Guides would predict poorer HrQoL over a one year period. We also examined 
whether different MBMD personality style scales predicted HrQoL. Because men 
recovering from treatment for prostate cancer must deal with physical limitations (Howlett 
et al., 2010; Katz, 2007; Litwin, Nied, & Dhanani, 1998; Penson, Litwin, & Aaronson, 2003; 
Potowsky et al., 2000; Wei et al., 2002), personality characteristics associated with 
interpersonal difficulties (communication and intimacy) and negative self-image may 
exacerbate emotional as well as physical aspects of HRQoL. We hypothesized that 
personality styles characterized by inhibition/avoidance, dejection, dependency, passive-
aggressiveness and low self-regard as measured on the MBMD would predict poorer HrQoL 
over the follow-up period. These personality characteristics have been theorized to be 
associated with greater difficulties in adjusting to illness and treatments for chronic medical 
conditions (Felton, Revenson & Hinrichsen, 1984; Taylor & Aspinwall, 1990; Weaver et al., 
2005). Additionally, in exploratory analyses, we also examined whether anxiety, depression, 
pessimism and specific MBMD health behavior-related indices predicted different domains 
of HrQoL.
Methods
Participants
Participants were men aged 45 years or older diagnosed with localized prostate cancer (stage 
T1a–T2b), and who had undergone either radical prostatectomy or radiotherapy within the 
past 18 months. Participants were included if they reported no prior history of cancer 
(excluding skin cancer) and no current adjuvant treatments. All participants were required to 
have at least a 9th grade education in order to understand the consent form and 
questionnaires. Individuals with cognitive impairment, e.g., < 23 on the Mini- Mental Status 
Examination (Folstein et al., 1975) were excluded. We also used the Structured Clinical 
Interview for Diagnostic and Statistical Manual of Mental Disorders, version IV (DSM-IV)/
Non-Patient edition (SCID-I/NP) to exclude individuals with active suicidal ideation, panic 
attacks, post-traumatic stress disorder, psychosis, or alcohol/drug dependence (First et al., 
2002).
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Procedures
Participants were recruited using flyers, community presentations, and urologist referral. 
Initial eligibility screening was conducted by telephone. Eligible men then completed an 
informed consent form approved by the University of Miami institutional review board. 
After enrollment, participants completed a battery of demographic, medical and 
psychosocial questionnaires. Participants were then reassessed at a 3-, 6- and 12-month 
follow-up and were compensated $50 at each visit.
Measures
Demographic/Medical Information—We assessed all relevant demographic/medical 
information including months since PC diagnosis and treatment and type of treatment 
(radical prostatectomy or radiation therapy) via self-report.
Millon Behavioral Medicine Diagnostic (MBMD)—The MBMD (Millon et al, 2001) 
is a self-report inventory designed to assess a comprehensive collection of psychosocial and 
behavioral factors that impact adjustment to illness and medical treatment outcomes. The 
test contains 165 true/false items and takes approximately 20–30 minutes to complete. The 
MBMD was validated on a heterogeneous sample of over 700 medical patients, ages 18 to 
85, with a variety of conditions, including heart disease, cancer, diabetes, chronic pain, and 
HIV/AIDS (Millon et al., 2001). The normative study found that the MBMD was both 
internally reliable (internal consistency coefficients mean α for all scales = 0.79), stable 
(test–retest reliability mean for all scales = 0.83) and demonstrated very good construct and 
convergent validity. The MBMD was completed at the baseline visit.
To test the utility of the MBMD as a screening tool in the context of treatment for localized 
PC, we focused on the two summary MBMD Management Guides. The Adjustment 
Difficulties scale assesses the risk of treatment complications due to the patient’s coping 
style, current psychological issues, personal resources, and health-related behaviors. The 
Psych Referral scale indicates the patient has sufficient difficulties that might benefit from 
psychosocial intervention. Separately, we also examined associations between MBMD 
Personality/Coping Styles and HrQoL over time. The MBMD Personality/Coping Style 
scales are designed to identify nonpsychiatric dimensions of DSM-IV Axis II personality 
issues that are particularly relevant to medical settings. (Millon et al., 2001).
In exploratory analyses, we examined the Depression and Tension-Anxiety Scales from the 
Psychiatric Indicators section and the Future Pessimism Scale from the Stress Moderators 
section of the MBMD. The Depression scale assesses the patient’s vegetative mood state 
and the tendency to view one’s life as misfortunate and to intensify the discomfort of 
problems while the Tension-Anxiety scale assesses the patient’s current levels of stress. The 
Future Pessimism Scale assesses the patient’s tendency to have a bleak outlook on life 
(Millon et al., 2001). Depression, anxiety and pessimism have been shown in prior work to 
be associated with poorer quality of life and negative health outcomes in persons recovering 
from surgery or dealing with chronic medical conditions (Antoni & Goodkin, 1988; Bremer, 
1995; Byrne et al., 1998; Scheier, Mathews, Owens et al., 1999; Taylor & Aspinwall, 1990). 
Finally we examined the two scales from the MBMD Treatment Prognostics section, 
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designed to identify health behavior factors that may influence medical treatment efficacy. 
The Interventional Fragility scale assesses whether patients will adjust emotionally to 
medical protocols and the Utilization Excess scale assesses the likelihood that patients will 
overuse medical services. We hypothesized that patients who have difficulties dealing with 
medical interventions and those who tend to be less satisfied with healthcare services would 
report poorer HrQoL over time.
HrQoL Measures—The main measure of HRQoL employed in this study was the 
Functional Assessment of Cancer Therapy (FACT), one of the most widely researched 
measures for assessing HrQoL in the field of psycho-oncology (Cella et al., 1993). The 27-
item instrument assesses well-being across several domains, and yields a total score that 
quantifies a cumulative HrQoL index and subscale scores based on the past 7 days. For the 
present study, the FACT total score and the physical and emotional well-being subscores 
were analyzed. The FACT has been used extensively with PC patients and has demonstrated 
excellent reliability and validity (Cella et al., 1993). We found that the FACT scores for the 
present sample were reliable (α = 0.77 – 0.89). The SF-36 (Ware & Sherbourne, 1992) was 
used to compliment the FACT in the present study. The measure consists of 36 items 
measuring mental and physical health functioning over the past month. We focused on the 
SF-36 Role Limitations due to Emotional Problems and Role Limitations due to Physical 
Problems subscales. The SF-36 has been used extensively with numerous medical 
populations including PC patients and has demonstrated excellent reliability and validity 
(Ware & Sherbourne, 1992). We found the SF-36 Role Limitations due to Emotional 
Problems (α = 0.89) and due to Physical Limitations (α = .87) subscales to have good 
reliability in this sample.
Statistical Analyses—We utilized multiple regression to test the main associations under 
investigation. All variable distributions were examined for outliers to assure normality. For 
regression analyses mean FACT and SF-36 scores at 12-month follow-up served as the 
HrQoL dependent measures. Baseline MBMD raw scores on the two Management Guides 
(Adjustment Difficulties, Psych Referral) served as our primary predictor variables and 
scores on the 11 Personality Style scales served as secondary variables. Finally, raw scores 
on the Treatment Prognostic scales Interventional Fragility and Utilization Excess, the Stress 
Moderator Pessimism scale, and Psychiatric Indicator scales Depression and Tension-
Anxiety served as our exploratory predictors. Based upon on prior work, raw scores were 
used rather than Prevalence Scores because raw scores are interval-scaled and may render 
more straightforward interpretations of analyses regarding the magnitude of associations 
with outcomes than do ordinally-scaled norm-based PS scores (Cruess et al., 2007, 2010; 
Farrell et al., 2011). Age, months since diagnosis, and baseline scores on each of the HrQoL 
measures as covariates were included in each of the regression analyses.
Results
Demographic and Medical Characteristics
A total of 66 men completed the MBMD at baseline (T1)1. Demographic and medical 
characteristics of the initial study sample of 66 men are presented in Table 1. The average 
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age was 68.18 (SD = 7.07) years. The majority was Caucasian (59%) and married (78%). 
The mean level of education was 13.83 (SD = 3.01) years. The majority was currently 
retired (64%) or employed full-time (20%). The mean time since PC diagnosis was 18.03 
(SD = 6.49) months, and the mean time since treatment (prostatectomy: 82%; radiotherapy: 
18%) was 12.18 (SD = 4.11) months.
Millon Behavioral Medicine Diagnostic (MBMD) Scores
Descriptive statistics for the MBMD are presented in Table 2. Within the sections of the 
MBMD, the scales with the greatest proportion of prevalence scores within the clinical 
range (> 75) were Respectful personality style (36%), Problematic Compliance (26%) and 
Adjustment Difficulties (29%). Overall, there was considerable variability in the MBMD 
raw scores and prevalence scores.
HrQoL Measures
Descriptive statistics for the HrQoL dependent measures are presented in Table 3. Of the 66 
participants completing the MBMD at T1, we were able to obtain matched HrQoL data on 
50 (76%) at T4. There were no significant differences between those with and without 
matched HrQoL data on any major demographic/medical variable (p’s >.10).
Regression Analyses Predicting HrQoL
Management Guides and HrQoL—The results of all regression analyses are presented 
in Table 4. There were significant inverse associations between both MBMD Management 
Guides (Adjustment Difficulties: β = −.43, p < .002; Psych Referral: β = −.48, p = .001) and 
FACT Total score at 12 month follow-up. Higher scores on the MBMD Adjustment 
Difficulties scale also predicted lower FACT Physical Well-being (β = −.37, p = .022), 
FACT Emotional Well-being (β = −.44, p = .002), SF-36 Role Limitations-Emotional (β = −.
44, p = .002), and SF-36 Role Limitations-Physical (β = −.42, p = .001) scores. Higher 
scores on the MBMD Psych Referral scale also predicted lower FACT Emotional Well-
being (β = −.47, p = .001), SF-36 Role Limitations-Emotional (β = −.44, p = .002) and 
SF-36 Role Limitations-Physical (β = −.37, p = .003) scores.
Personality Styles and HrQoL—Of the Personality/Coping Style scales, higher scores 
on the Introversive Style scale predicted lower FACT Emotional Well-being (β = −.28, p = .
048) and SF-36 Role Limitations-Emotional (β = −.34, p = .018) scores. Similarly, higher 
scores on the Inhibited Style scale predicted lower FACT Emotional Well-being (β = −.41, p 
= .005) and SF-36 Role Limitations-Emotional (β = −.38, p = .012) scores. Higher Dejected 
Style scores predicted lower FACT Emotional Well-being (β = −.37, p = .016) scores. 
Higher Cooperative Style scores predicted lower FACT total (β = −.36, p = .002), FACT 
Physical Well-being (β = −.33, p = .012), FACT Emotional Well-being (β = −.50, p < .001) 
and SF-36 Role Limitations-Emotional (β = −.50, p < .001) scores. Higher Oppositional 
Style scores predicted lower FACT Emotional Well-being (β = −.36, p = .018) and SF-36 
Role Limitations-Emotional (β = −.35, p = .020) scores. Additionally, higher Denigrated 
Style scores predicted lower FACT total (β = −.33, p = .018), FACT Physical Well-being (β 
= −.34, p = .029), FACT Emotional Well-being (β = −.35, p = .029) and SF-36 Role 
Limitations-Emotional (β = −.50, p = .002) scores. In contrast Sociable, Confident, Forceful, 
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Non-conforming and Respectful scales did not predict HrQoL scores in this sample (see 
Table 4).
Psychiatric Indicators, Stress Moderators and HrQoL—Higher scores on the 
Depression scale predicted lower FACT Emotional Well-being (β = −.42, p = .013) and 
lower SF-36 Role Limitations-Emotional (β = −.38, p = .011) scores. Higher Tension-
Anxiety scales predicted lower FACT Total (β = −.29, p = .029), FACT Emotional Well-
being (β = −.39, p = .010) and SF-36 Role Limitations-Emotional (β = −.39, p = .006) 
scores. Greater Future Pessimism scores were not associated with FACT scores but were 
associated with lower SF-36 Role Limitations due to Emotional Problems (β = −.30, p = .
044) and lower SF-36 Role Limitations due to Physical Problems (β = −.29, p = .029) 
scores.
Treatment Prognostics scales and HrQoL—Higher scores on the Interventional 
Fragility scale predicted lower FACT total (β = −.38, p = .003), FACT Physical Well-being 
(β = −.41, p = .002), FACT Emotional Well-being (β = −.53, p < .001) and SF-36 Role 
Limitations-Emotional (β = −.38, p = .007) scores. Higher scores on the Utilization Excess 
scale predicted lower FACT total (β = −.34, p = .008), FACT Emotional Well-being (β = −.
44, p = .002) and SF-36 Role Limitations-Emotional (β = −.45, p = .001) scores.
Discussion
The major results of this study indicate that the MBMD may be a valuable predictor of 
multiple domains of HrQoL over time in men treated for PC and may serve as a screening 
tool for determining those men most likely to benefit from adjunctive psychosocial 
interventions. While remarkable strides have been made in curative treatments for PC, these 
treatments, typically involving surgery or radiation, can cause acute and chronic side effects 
including urinary, bowel and erectile dysfunction, fatigue and impaired physical functioning 
(Potosky et al., 2007; Stanford et al., 2000). Declines in functioning have been seen to 
persist for years following primary treatment (Penson et al., 2003; Potosky et al., 2000) and 
have been shown to be more severe than that which would be expected due to age-related 
morbidity alone (Hoffman et al., 2004; Wei et al., 2002). In some men these side effects 
compromise health-related quality of life (HrQoL) and may be a persistent source of concern 
and bother over an extended period after treatment completion (Penson et al., 2003; Schover 
et al., 2002; Cooperberg et al., 2003; Wei et al., 2002). Interestingly, despite differences in 
trajectories of disease-specific side effects, prostate cancer surgery and radiation patients 
often report similar levels of more general domains of HrQoL (Penson et al., 2003; Potosky 
et al., 2000), suggesting that other factors may be involved in predicting long-term changes 
in HrQoL following PC treatment.
Less is known about the role of individual differences in mental functioning and personality 
as predictors of how well men maintain their HrQoL over the year after PC treatment. In the 
context of a larger prospective study the present analyses tested whether the MBMD (Millon 
et al, 2001), predicted indicators of HrQoL in men who had undergone treatment for PC and 
been followed for a 12-month period. This is the first study to evaluate the utility of this test 
in men treated for PC. We specifically tested the utility of the MBMD Management Guides 
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and Personality/Coping Styles, as well as select Treatment Prognostic, Stress Moderator, 
and Psychiatric Indicator scales in predicting commonly used HrQoL indicators at 12 month 
follow-up in men who had been treated with either surgery (radical prostatectomy) or 
radiation therapy for localized disease.
While scores on the HrQoL measures were within the normative range for the general U.S. 
adult population, adult male cancer samples, and men diagnosed with PC (Brucker et al., 
1990; Schlenk et al., 1998), the MBMD Management Guides (reflecting psychosocial 
adjustment difficulties and need for mental health referral) were strongly associated with 
poorer overall HrQoL and emotional and physical HRQoL across the follow-up period. 
Predictive relationships were observed after controlling for relevant demographic and 
medical variables and baseline HrQoL scores. The results point to the utility of these 
MBMD Management Guides in screening those cancer patients most likely to suffer 
emotional and physical HrQoL deficits over time.
It is known that cancer patients may be at increased risk for experiencing post-treatment 
decrements in quality of life depending on pre-treatment psychological comorbidity (e.g., 
Trentham-Dietza, Remington, Moinpourc, Hamptona, Sappa, & Newcomba, 2003). 
Endorsement of psychological difficulties (e.g., anxiety, depression) have been associated 
with worse long-term quality of life (Harrison et al., 2011; Reich, Lesur, & Perdrizet-
Chevallier, 2008; Schag, Ganz, Wing, Sim, & Lee, 1994), suggesting that those patients 
with premorbid difficulties may be in greater need for psychosocial intervention efforts 
(Burton, Parker, Farrell, Conneely, Booth, & Elcombe, 2007; Jacobsen & Jim, 2008). 
Results of the present study support this notion, as we found that the Depression and 
Tension-Anxiety scales of the MBMD, were also associated with lower HrQoL scores at 
follow-up. These findings suggest that the MBMD Psychiatric Indicators may be useful in 
identifying those PC patients in greatest need of such services.
We also found evidence that personality styles characterized by inhibition or avoidance, 
dependency, passive-aggressiveness or low self-regard (self-denigration) predicted poorer 
HrQoL over time in these men. These scales seemed to almost exclusively predict 
emotionally related HrQoL scales. There were no associations between MBMD Sociable, 
Confident, Forceful, Non-Conforming, and Respectful personality style scores and HrQoL 
outcomes. Research suggests that personality traits and coping strategies may be linked to 
global HrQOL outcomes among men with PC. Previously, avoidance, behavioral 
disengagement, blaming oneself, and engaging in wishful thinking have all been associated 
with negative physical and psychological adjustment in men with PC (Perczek, 1999; Ptacek 
et al., 1999; Roesch et al., 2005). Additionally, Helgeson & Lepore (1997) reported that men 
treated for PC who were characterized by independence, activeness, self-confidence and 
competitiveness (i.e., “agency”) reported better post-treatment physical and mental 
adjustment, whereas those characterized by arrogance, cynicism, and hostility (i.e., 
“unmitigated agency”) reported poorer mental adjustment. Although results indicate that 
individuals who employ avoidant coping strategies may be at increased risk for greater 
decrements in HrQoL, some studies show that avoidant strategies immediately after 
diagnosis may prevent an individual from becoming overwhelmed if their coping resources 
are limited (see Roesch et al., 2005). The key may be in whether the use of avoidant 
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strategies persists well after treatment is completed. In sum, while preliminary support for 
the role of personality processes in overall mental adjustment to PC has accrued, evidence 
for whether personality traits predict HrQOL outcomes has been lacking. The present 
prospective study contributes to this body of literature by clarifying some of these 
relationships in men who were followed systematically over a 12-month observation period.
Of the MBMD Treatment Prognostics scales, higher scores on Interventional Fragility and 
Utilization Excess, indicative of having more difficulty with invasive medical procedures 
and over-utilizing health services, respectively, were also consistently related to poorer 
HrQoL over time. These results suggest that men who have initial difficulties recovering 
from procedures such as surgery or radiation may also have greater problems over an 
extended follow-up period. It is plausible that elevations in Interventional Fragility scores in 
the period shortly after treatment may provide a screening tool for identifying those men 
who might benefit from psychological interventions to facilitate longer-term adjustment. In 
terms of the association between the Utilization Excess scale and HrQoL outcomes, several 
recent studies have shown that improper utilization of cancer services may have a 
detrimental impact on morbidity and mortality (Hanchate et al., 2010; Alemayehu et al., 
2010), and identifying patients with such issues may assist in enhancing HrQoL outcomes. 
Scales referring to information discomfort, medication adherence and compliance with 
lifestyle changes did not appear relevant in predicting HrQoL over time. This is not 
surprising in that this sample is not dealing with newly emerging medical information, or 
complex medication or self-care regimens.
Finally we found greater Future Pessimism scores predicted lower SF-36 Role Limitations 
due to Emotional Problems scale at 12 month follow-up. This is consistent with the 
construct of Future Pessimism. Patients with elevations on this scale are seen as more prone 
to disengaging and giving up when faced with challenges and are therefore likely to view 
continued emotional problems as insurmountable and role-limiting (Millon et al., 2001).
There were several limitations in the study. The results of analyses presented here are based 
on a post-hoc study of a sub-sample of men drawn from a larger study of psychosocial 
adjustment after treatment for prostate cancer treatment. Because the MBMD was added to 
the test battery midway through the larger study, our sample size was somewhat limited for 
predictive analyses. Although we had sufficient power to discern moderate to strong effect 
sizes, future research should employ the MBMD in a larger sample of PC patients. Another 
limitation was the timing of the MBMD assessment since the point of entry into the study 
was on average about one year after the completion of treatment; future work should 
consider an MBMD assessment soon after diagnosis and then follow men for HrQoL 
assessments throughout treatment and beyond. The sample of men studied here were 
predominantly non-Hispanic white middle class men, who presumably had received the 
standard of care for PC and who had optimal access to post-treatment resources. The results 
therefore may not generalize to ethnic minority men or those of lower socioeconomic status 
who may not enjoy such access (Krupski, Sonn, Kwan, Maliski, Fink & Litwin, 2005). 
Future work will need to explore the role of personality factors in HRQoL outcomes in these 
groups of men dealing with PC. Since this cohort of men was treated with either 
prostatectomy or radiation, the present results suggest that these scales may have predictive 
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validity in types of treatment for early stage PC that were practiced in the past few decades 
(Stanford et al., 1999). However, whether these psychosocial characteristics will predict 
HrQoL in men experiencing newer, less invasive approaches to treating this disease (i.e., 
active surveillance, (Albertson, Hanley, & Fine, 2005; Bill-Axelson et al., 2008) is yet to be 
seen. Finally, we cannot generalize these findings to populations diagnosed with other 
cancer types or those at later stages of disease, and future work should utilize the MBMD 
with other cancer patient groups dealing with treatment-related quality of life issues.
In conclusion, the MBMD Management Guide summary indicators significantly predicted 
poorer total, emotional and physical domains of HrQoL over time among men recently 
treated for PC. Scores on the Depression, and Tension-Anxiety Psychiatric Indicator scales 
mirrored these findings. Furthermore, men revealing higher scores in personality styles 
characterized by inhibition/avoidance, dependency, depression, passive-aggressiveness or 
self-denigration showed poorer HrQoL over time. Exploratory analyses revealed that higher 
scores on Interventional Fragility, Utilization Excess, and Future Pessimism scales also 
predicted poorer HrQoL in this sample. Clinicians and researchers might consider utilizing 
the MBMD to help screen for patients treated for PC who are most likely to report poorer 
HrQoL over time and provide psychosocial support earlier to enhance their physical and 
mental health functioning over time. A better understanding of psychosocial factors that 
impact PC patients may help identify those patients in need of counseling to facilitate 
adjustment to the persisting sequelae of treatment.
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Table 1
Demographic and medical characteristics of the participants (N=66)
Baseline characteristic Descriptive/Group Value
Age in years Mean (SD) 68.18 (7.07)
Education in years Mean (SD) 13.83 (3.01)
Income in $1,000 Mean (SD) 53.44 (45.20)
Marital Status: n (%)
Single, never married 5 (7.57%)
Married or in an equivalent relationship 52 (78.78%)
Separated 3 (44.54%)
Divorced 5 (7.57%)
Widowed 1 (1.51%)
Ethnic Group: n (%)
Anglo/Caucasian/European American (not Hispanic) 39 (59.09%)
Black/African-American 4 (6.06%)
Caribbean Islander 4 (6.06%)
Black, of origin other than those above 1 (1.52%)
Asian/Asian-American 0 (0.0%)
Cuban/Cuban-American 9 (13.64%)
Other Hispanic 9 (13.64%)
Employment status: n (%)
Employed full-time 13 (19.70%)
Employed part-time 4 (6.06%)
On disability 1 (1.52%)
Retired 42 (63.64%)
Otherwise not employed 6 (9.09%)
Time since diagnosis in months Mean (SD) 18.03 (6.49)
Time since treatment in months Mean (SD) 12.18 (4.11)
Treatment type: n (%)
Radical prostatectomy 12 (18.18%)
Radiation therapy 54 (81.82%)
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Table 2
Descriptive statistics for the Millon Behavioral Medicine Diagnostic (N=66)
MBMD domain MBMD subscale Raw score Prevalence
score
Prevalence score
≥75
Mean (SD) Mean (SD) n (%)
Psychiatric indications
Anxiety–tension 5.47 (7.18) 45.92 (26.86) 10 (15.15%)
Depression 5.92 (7.01) 46.70 (28.91) 15 (22.72%)
Cognitive dysfunction 4.38 (4.98) 34.48 (19.79) 1 (1.51%)
Emotional lability 6.41 (5.81) 46.45 (20.37) 4 (6.06%)
Guardedness 10.24 (6.01) 54.70 (19.12) 9 (13.63%)
Coping styles
Introversion 6.74 (5.67) 52.29 (26.70) 14 (21.21%)
Inhibited 4.18 (5.64) 48.11 (26.34) 5 (7.57%)
Dejected 2.33 (4.33) 27.80 (31.14) 6 (9.09%)
Cooperative 7.24 (5.10) 51.18 (21.71) 9 (13.63%)
Sociable 11.45 (4.28) 57.17 (16.22) 9 (13.63%)
Confident 11.98 (4.37) 59.05 (16.93) 9 (13.63%)
Nonconforming 9.23 (5.39) 48.11 (17.74) 3 (4.54%)
Forceful 8.98 (5.59) 41.53 (19.51) 2 (3.03%)
Respectful 20.71 (6.17) 60.00 (23.57) 24 (36.36%)
Oppositional 8.67 (7.02) 52.53 (21.77) 3 (4.54%)
Denigrated 4.68 (5.26) 47.17 (24.80) 5 (7.57%)
Stress moderators
Illness apprehension 8.67 (8.73) 49.50 (25.37) 13 (19.69%)
Functional deficits 8.98 (7.47) 59.09 (24.26) 15 (22.72%)
Pain sensitivity 9.83 (9.27) 53.86 (26.53) 16 (24.24%)
Social isolation 5.09 (6.01) 49.35 (26.12) 8 (12.12%)
Future pessimism 7.08 (6.62) 53.53 (22.80) 13 (19.69%)
Spiritual absence 7.45 (8.54) 46.98 (37.10) 20 (30.30%)
Treatment prognostics
Interventional fragility 4.73 (6.07) 38.42 (23.85) 4 (6.06%)
Medication abuse 2.35 (2.87) 41.39 (23.81) 4 (6.06%)
Information discomfort 1.47 (2.00) 32.29 (29.06) 8 (12.12%)
Utilization excess 6.39 (5.26) 55.26 (21.36) 9 (13.63%)
Problematic compliance 7.86 (6.27) 54.24 (27.52) 17 (25.75%)
Management guides
Adjustment difficulties 4.67 (4.01) 66.89 (19.96) 19 (28.78%)
Psych referral 3.12 (3.17) 44.03 (21.79) 10 (15.15%)
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Table 3
Descriptive statistics for the SF-36 and FACT-P outcomes measures
T4
Measure Subscale Mean (SD)
SF-36
Role Limitations Physical 71.50 (38.14)
Role Limitations Emotional 83.33 (33.84)
FACT-P
Physical Well-being 24.23 (4.93)
Emotional Well-being 20.78 (4.36)
Total Well-being score 87.96 (16.09)
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